Top-Rated StocksTop-RatedNYSE:CATX Perspective Therapeutics (CATX) Stock Price, News & Analysis $3.60 +0.21 (+6.19%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$3.60 0.00 (0.00%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Perspective Therapeutics Stock (NYSE:CATX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CATX alerts:Sign Up Key Stats Today's Range$3.40▼$3.6950-Day Range$2.16▼$4.1152-Week Range$1.60▼$16.55Volume511,203 shsAverage Volume1.08 million shsMarket Capitalization$267.22 millionP/E RatioN/ADividend YieldN/APrice Target$12.56Consensus RatingBuy Company Overview Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. Read More Perspective Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreCATX MarketRank™: Perspective Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 804th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePerspective Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Perspective Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.20) per share.Price to Book Value per Share RatioPerspective Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Perspective Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.38% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPerspective Therapeutics does not currently pay a dividend.Dividend GrowthPerspective Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.38% of the float of Perspective Therapeutics has been sold short.Short Interest Ratio / Days to CoverPerspective Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Perspective Therapeutics has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Perspective Therapeutics this week, compared to 5 articles on an average week.Search Interest20 people have searched for CATX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.72% of the stock of Perspective Therapeutics is held by insiders.Percentage Held by Institutions54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Perspective Therapeutics' insider trading history. Receive CATX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CATX Stock News HeadlinesCATX - Perspective Therapeutics Inc Executives - Morningstar1 hour ago | morningstar.comMResearch Analysts Set Expectations for CATX Q2 EarningsJune 26, 2025 | americanbankingnews.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 5 at 2:00 AM | Porter & Company (Ad)B. Riley Raises Perspective Therapeutics (NYSE:CATX) Price Target to $12.00June 25, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), Ocular Therapeutix (OCUL) and Vertex Pharmaceuticals (VRTX)June 25, 2025 | theglobeandmail.comPerspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical TrialJune 21, 2025 | finance.yahoo.comPerspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual MeetingJune 21, 2025 | globenewswire.comPerspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical TrialJune 21, 2025 | globenewswire.comSee More Headlines CATX Stock Analysis - Frequently Asked Questions How have CATX shares performed this year? Perspective Therapeutics' stock was trading at $3.19 on January 1st, 2025. Since then, CATX stock has increased by 12.9% and is now trading at $3.60. How were Perspective Therapeutics' earnings last quarter? Perspective Therapeutics, Inc. (NYSE:CATX) announced its earnings results on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, meeting analysts' consensus estimates of ($0.21). The company earned $0.37 million during the quarter. Perspective Therapeutics had a negative trailing twelve-month return on equity of 27.40% and a negative net margin of 4,096.66%. When did Perspective Therapeutics' stock split? Perspective Therapeutics's stock reverse split before market open on Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Perspective Therapeutics? Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Perspective Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Chevron (CVX). Company Calendar Last Earnings11/12/2024Today7/05/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:CATX Previous SymbolNYSE:CATX CIK728387 Webwww.perspectivetherapeutics.com Phone206-676-0900Fax509-267-3670Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$12.56 High Stock Price Target$20.00 Low Stock Price Target$5.00 Potential Upside/Downside+248.8%Consensus RatingBuy Rating Score (0-4)3.18 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.51 million Net Margins-4,096.66% Pretax Margin-3,780.02% Return on Equity-27.40% Return on Assets-23.16% Debt Debt-to-Equity RatioN/A Current Ratio9.60 Quick Ratio9.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book1.35Miscellaneous Outstanding Shares74,228,000Free Float65,209,000Market Cap$267.22 million OptionableOptionable Beta1.18 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSE:CATX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.